Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients.
The effectiveness of ceftolozane/tazobactam for the treatment of infections in neutropenic patients caused by hypervirulent multidrug-resistant (MDR) Pseudomonas aeruginosa has not been previously reported. We identified seven cases of MDR P. aeruginosa infection in neutropenic patients over a four-month period within the same hematology ward. Four cases were associated with rapid progression despite piperacillin-tazobactam or meropenem therapy, and three patients developed sepsis or extensive skin/soft tissue necrosis. In three of the four cases, patients were empirically switched from meropenem to ceftolozane/avibactam before carbapenem susceptibility test results were available, and all four patients underwent extensive surgical debridement or amputation of affected tissues and survived. Further investigation revealed a common bathroom source of MDR P. aeruginosa clonal subtypes ST175 and ST235 that harbored genes for type III secretion system expression and elaboration of ExoU or ExoS exotoxin. We conclude that ceftolozane/tazobactam plus early source control was critical for control of rapidly progressing skin and soft infection in these neutropenic patients caused by highly virulent ST175 and ST235 clones of MDR P. aeruginosa.
['Coppola|Paolo E|PE|', 'Gaibani|Paolo|P|', 'Sartor|Chiara|C|', 'Ambretti|Simone|S|', 'Lewis|Russell E|RE|0000-0002-2002-4339', 'Sassi|Claudia|C|0000-0002-7864-2586', 'Pignatti|Marco|M|0000-0002-8259-496X', 'Paolini|Stefania|S|', 'Curti|Antonio|A|', 'Castagnetti|Fausto|F|', 'Ursi|Margherita|M|', 'Cavo|Michele|M|', 'Stanzani|Marta|M|']
hypervirulent Pseudomonas aeruginosa ceftolozane/tazobactam hematological malignancy neutropenia skin and soft tissue